First identification of an Escherichia coli clinical isolate producing both metalloβ-lactamase VIM-2 and extended-spectrum β-lactamase IBC-1  by Galani, I et al.
A C K N O W L E D G E M E N T S
E. Machado was supported by a fellowship from the Fundac¸a˜o
para a Cieˆncia e a Tecnologia (SFRH ⁄BD ⁄ 11304 ⁄ 2002).
R E F E R E N C E S
1. Bonnet R. Growing group of extended-spectrum b-lacta-
mases: the CTX-M enzymes. Antimicrob Agents Chemother
2004; 48: 1–14.
2. Cao V, Lambert T, Courvalin P. ColE1-like plasmid pIP843
of Klebsiella pneumoniae encoding extended spectrum
b-lactamase CTX-M-17. Antimicrob Agents Chemother 2002;
46: 1212–1217.
3. Karim A, Poirel L, Nagarajan S, Nordmann P.
Plasmid-mediated extended-spectrum-beta-lactamase
(CTX-M-3-like) from India and gene association with
insertion sequence ISEcp1. FEMS Microbiol Lett 2001; 201:
237–241.
4. Bou G, Cartelle M, Tomas M et al. Identification and broad
dissemination of the CTX-M-14 beta-lactamase in different
Escherichia coli strains in the northwest area of Spain. J Clin
Microbiol 2002; 40: 4030–4036.
5. Valverde A, Coque TM, Baquero F, Canto´n R. Significant
increase in prevalence of human fecal carriage of exten-
ded-spectrum b-lactamase-producing Enterobacteriaceae
during the last decade: towards endemicity? [abstract C2-
38]. In: Program and abstracts of the 43rd Annual Interscience
Conference on Antimicrobial Agents and Chemotherapy.
Washington DC: American Society for Microbiology, 2003;
105.
6. Coque TM, Varela MC, Machado E et al. The cefotaxi-
mases (CTX-M-9 and CTX-M-10) invasion of Spain: dis-
persal among different enterobacterial species, clones, and
plasmids [abstract C2-646]. In: Program and abstracts of the
42nd Annual Interscience Conference on Antimicrobial Agents
and Chemotherapy. Washington DC: American Society for
Microbiology, 2002; 96.
7. National Committee for Clinical Laboratory Standards.
Performance standards for antimicrobial disk susceptibility tests.
M2-A7. Wayne, PA: NCCLS, 2000.
8. Coque TM, Oliver A, Pe´rez-Dı´az JC, Baquero F, Canto´n R.
Genes encoding TEM-4, SHV-2, and CTX-M-10 extended-
spectrum beta-lactamases are carried by multiple Klebsiella
pneumoniae clones in a single hospital (Madrid 1989–2000).
Antimicrob Agents Chemother 2002; 46: 500–510.
9. Poirel L, Decousser JW, Nordmann P. Insertion sequence
ISEcp1B is involved in expression and mobilization of a
blaCTX-M b-lactamase gene. Antimicrob Agents Chemother
2003; 47: 2938–2945.
10. Saladin M, Cao VT, Lambert T et al. Diversity of CTX-M
beta-lactamases and their promoter regions from Entero-
bacteriaceae isolated in three Parisian hospitals. FEMS
Microbiol Lett 2002; 209: 161–168.
11. Chanawong A, M’Zali FH, Heritage J, Xiong JH, Hawkey
PM. Three cefotaximases, CTX-M-9, CTX-M-13, and CTX-
M-14, among Enterobacteriaceae in the People’s Republic of
China. Antimicrob Agents Chemother 2002; 46: 630–637.
12. Pai H, Choi EH, Lee HJ, Hong JY, Jacoby GA. Identifica-
tion of CTX-M-14 extended-spectrum b-lactamase in
clinical isolates of Shigella sonnei, Escherichia coli, and
Klebsiella pneumoniae in Korea. J Clin Microbiol 2001; 39:
3747–3749.
13. Brin˜as L, Moreno MA, Zarazaga M et al. Detection of
CMY-2, CTX-M-14, and SHV-12 beta-lactamases in
Escherichia coli fecal-sample isolates from healthy chickens.
Antimicrob Agents Chemother 2003; 47: 2056–2058.
RESEARCH NOTE
First identification of an Escherichia coli
clinical isolate producing both metallo-
b-lactamase VIM-2 and extended-spectrum
b-lactamase IBC-1
I. Galani, M. Souli, Z. Chryssouli, D. Katsala
and H. Giamarellou
4th Department of Internal Medicine, Molecular
Biology Section, University of Athens Medical
School, Athens, Greece
A B S T R A C T
An Escherichia coli strain with decreased suscepti-
bility to carbapenems was isolated from a hospi-
talised patient in Athens, Greece. The strain was
resistant to all b-lactams, including aztreonam,
whereas the MIC of imipenem and meropenem
was 0.5 mg ⁄L. A positive EDTA–disk synergy test
suggested the production of ametallo-b-lactamase.
PCR experiments revealed the presence of the
blaVIM-2, blaIBC-1 and blaTEM-1 genes. Resistance to
b-lactamswasnot transferable by conjugation. This
is the first report of a clinical isolate of E. coli pro-
ducingVIM-2, and the first report of the coexistence
of blaVIM-2 and blaIBC-1 in a single clinical isolate.
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Metallo-b-lactamases (MBLs) of the VIM type are
integron-borne enzymes that can be either chrom-
osomally-encoded or plasmid-mediated. With
the exception of aztreonam, they hydrolyse all
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b-lactams, including the carbapenems. They are
susceptible to inhibition by divalent ion chelators
such as EDTA, but not to b-lactamase inhibitors
such as clavulanate. The VIM-2 enzyme has been
described previously in Europe [1,2] and the Far
East [3–7], mostly in Pseudomonas aeruginosa [1–3],
but also in Citrobacter freundii [4], Pseudomonas
putida [3], Pseudomonas stutzeri [5], Serratia marces-
cens [6] and Acinetobacter baumannii [7].
The IBC-1 enzyme is a novel integron-associ-
ated class A extended-spectrum b-lactamase that
hydrolyses all b-lactams except the cephamycins
and the carbapenems. It has been described in an
Enterobacter cloacae isolate from Thessaloniki,
Greece [8], and has been involved in an outbreak
in a neonatal intensive care unit in the same area
[9]. Its presence has also been documented in a
clinical isolate of Escherichia coli from a patient in
Athens, Greece [10].
This report describes a clinical isolate of E. coli
with resistance to extended-spectrum cephalo-
sporins, cefoxitin and aztreonam, as well as
reduced susceptibility to carbapenems, associated
with production of both VIM-2 and IBC-1. This is
the first report of VIM-2 in E. coli worldwide, and
the first report of the coexistence of the blaVIM-2
and blaIBC-1 genes in a single isolate.
The E. coli strain was isolated in 2001 from the
bronchial secretions of a patient hospitalised in a
tertiary care hospital in Athens, Greece. b-Lactam
MICs were determined by standard methods [11].
A double-disk synergy test with imipenem- and
EDTA-containing disks [12] was used to screen
for MBL production.
Conjugation experiments were performed by
both the broth and filter mating techniques, with
E. coli K12 strain RC85 R– (rifampicin-resistant;
MIC >128 mg ⁄L) as the recipient [13]. Transcon-
jugants were selected on agar supplemented
with rifampicin (128 mg ⁄L) and ceftazidime (16
mg ⁄L). Isoelectric focusing of sonic extracts was
performed on precast polyacrylamide gels with a
pH 3–10 gradient. TEM-1 (pI 5.4), TEM-4 (pI 5.9)
and TEM-3 (pI 6.3) enzymes, produced by refer-
ence strains, were used as standards with known
pIs for b-lactamase characterisation.
PCR amplification was performed as described
previously: with VIM-B (5¢-ATGGTGTTTGGTC
GCATATC-3¢) and VIM-F (5¢-TGGGCCATTC
AGCCAGATC-3¢) primers, which amplified a
510-bp (nucleotides 152–661) internal fragment
of the blaVIM gene (EMBL ⁄GenBank accession no.
AF 191564) [1]; with IBC-1A (5¢- TGCATCG-
GAAAAATTAACCT-3¢) and IBC-1B (5¢-AATTT-
TACGAAATATGCG-3¢) primers, which amplified
a 400-bp (nucleotides 51–450) internal fragment of
the blaIBC-1 gene (GenBank accession no. AF
208529) [8]; and for the blaTEM-1 gene [14]. PCR
products were cloned and sequenced by standard
molecular biology methods. PCR–restriction frag-
ment length polymorphism (PCR-RFLP) analysis
of the 510-bp PCR amplicon corresponding to the
internal fragment of the blaVIM gene was per-
formed with SacI restriction endonuclease to
screen for the presence of a gene belonging to
the blaVIM-1 cluster. Previous unpublished obser-
vations from our group suggest that PCR-RFLP
analysis can be used to differentiate between the
two gene clusters containing blaVIM-1 (blaVIM-1,
blaVIM-4, blaVIM-5) and blaVIM-2 (blaVIM-2, blaVIM-3,
blaVIM-6, blaVIM-8, blaVIM-9, blaVIM-10), as a SacI
restriction site is present at position 515 in genes
belonging to the blaVIM-1 cluster.
The clinical isolate of E. coli was resistant to
ampicillin, ampicillin–sulbactam, piperacillin,
piperacillin–tazobactam, cefalothin, cefoxitin,
cefotaxime, ceftriaxone, ceftazidime and aztreo-
nam. It was also resistant to trimethoprim–sulpha-
methoxazole, ciprofloxacin and tobramycin, and
intermediately resistant to amikacin, but retained
susceptibility to gentamicin and tetracycline.MICs
of imipenem and meropenem for the isolate were
0.5 mg ⁄L, whereas those of ceftazidime, cefotaxi-
me, cefepime and aztreonam were > 512, 16, 2 and
32 mg ⁄L, respectively. The isolate gave a positive
result in the EDTA–disk synergy test, and isoelec-
tric focusing showed three b-lactamase bands with
pI values of c. 5.4, 5.8 and 6.9, corresponding to
TEM-1, VIM-2 and IBC-1, respectively. Neither
imipenem nor ceftazidime resistance was trans-
ferred by conjugation. PCR-RFLP analysis of the
blaVIM amplicon suggested the presence of a
blaVIM-2 variant. PCR amplification and nucleotide
sequence analysis revealed that the clinical isolate
carried blaTEM-1, blaVIM-2 and blaIBC-1.
The spread of MBLs in Enterobacteriaceae is a
matter of concern in Greece. Outbreaks caused by
VIM-1-producing Klebsiella pneumoniae strains
have been described in several hospitals in Athens
[15], and a sporadic strain ofE. coli carrying blaVIM-1
was isolated at a tertiary hospital in Athens [16].
MBLs of the VIM type, which are well-established
in P. aeruginosa strains in Greek hospitals [2,17,18],
havenowbeen introduced intoEnterobacteriaceae.
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Clinical isolates ofEnt. cloacae and E. coliproducing
IBC-1 have, until now, been reported only from
Greece, and the class 1 integrons carrying these
genes have been well-characterised [8,10]. The
present study provides the first description of the
coexistence of blaVIM-2 and blaIBC-1 in a single
isolate. VIM- and IBC-encoding genes appear to
be located in mobile gene cassettes inserted into
integrons, which accounts for their enhanced
spread. It is possible that a single integron is the
vehicle for both genes in the E. coli isolate reported
in the present study. Repeated attempts to transfer
either gene to anE. coli recipientwere unsuccessful,
suggesting that these genes were located either on
non-transferable plasmids or on the chromosome,
as was the case for blaVIM-1 and blaVIM-3 in
P. aeruginosa [5,19]. The carbapenem MICs for the
E. coli isolate studied were below the resistance
breakpoint, but it has been noted previously
that MBLs confer only a low level of resistance
to carbapenems in Enterobacteriaceae unless
another mechanism, such as impaired outer-mem-
brane permeability, is also present. Aztreonam
resistance in the isolate was probably associated
with IBC-1, since monobactams are stable to
hydrolysis by carbapenemases. Furthermore, the
cefepime MIC was consistent with previous
reports of the weak hydrolytic activity of both
IBC-1 and VIM-2 against cefepime [1,10].
The difficulties in detecting MBL-producing
strains in the clinical microbiology laboratory,
together with the mobile nature of the gene
cassettes carrying the VIM-type enzymes, may
facilitate their dissemination. The coexistence of
MBLs and non-MBL extended-spectrum b-lacta-
mases in the same strain complicates the situation
further. These observations highlight the chal-
lenge for clinical microbiologists and infectious
disease specialists in detecting these strains, so
that infection control measures and appropriate
treatment can be implemented in a timely manner.
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A B S T R A C T
An omnibus survey of microbiologists (n = 400)
and a survey of participants (n = 49) in the
Meropenem Yearly Susceptibility Test Informa-
tion Collection (MYSTIC) programme were
conducted to determine the awareness and
prevalence of extended-spectrum b-lactamases
(ESBLs), and the regularity and method of screen-
ing. Of the omnibus survey participants, 69%
screened regularly for ESBLs, compared with
83% of MYSTIC participants. In both surveys,
ESBLs were more common in Klebsiella pneumoni-
ae (73% and 79%, respectively) and Escherichia coli
(63% and 81%, respectively) than in other bac-
teria. The surveys demonstrated that awareness
of, and testing for, ESBLs is inconsistent.
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In order to make informed prescribing decisions,
clinicians need accurate information on the likely
antibiotic resistance profile of the organism caus-
ing the infection. Surveillance studies, such as the
Alexander Project, SENTRY and the Meropenem
Yearly Susceptibility Test Information Collection
(MYSTIC) programme, have been useful in pro-
viding accurate prevalence rates of specific bac-
terial resistance caused by different mechanisms,
such as extended-spectrum b-lactamases (ESBLs)
[1–3]. Infections caused by ESBL-producing path-
ogens may be associated with increases in mor-
tality, duration of hospital stay and hospital costs
[4,5]. However, awareness of the clinical import-
ance of ESBL-producing strains may vary consid-
erably among clinicians and microbiologists, with
continued surveillance and testing not performed
widely, and especially when the prevalence of
resistance is low. Therefore, two global surveys,
an omnibus survey and a survey of participants in
the MYSTIC programme, were conducted to
determine the degree of awareness of ESBLs, the
methods and frequency of ESBL screening, and
the reasons for not screening.
The omnibus survey comprised a panel of
microbiologists who participate regularly in tele-
phone interviews conducted by ISIS Research
(Putney, London, UK), an independent market
research agency. The respondents were not given
advance notice of the questions, and so were
asked to give an estimate when asked for
percentages. All participants in the MYSTIC
programme were sent a questionnaire. The two
surveys were performed during February and
March 2002. Both surveys included similar ques-
tions relating to perception of the incidence of
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